Computer System Validation (CSV) and CSA for Pharma
Computer System Validation (CSV) is the process of confirming that a computerised system consistently produces a result meeting its predetermined specifications. FDA's Computer Software Assurance (CSA) guidance (2022) modernises the approach — shifting from documentation volume to critical thinking and risk-based evidence.
Traditional CSV vs modern CSA approach
Traditional CSV emphasises scripted testing of every function, detailed test scripts and extensive documentation. FDA's CSA guidance recognises that scripted testing of well-understood, low-risk functions adds cost without adding safety. CSA focuses validation effort on critical functions — regulated records, calculations, audit trails, e-signatures — and accepts vendor test documentation for non-critical functions.
Critical functions in pharma MES validation
For a pharmaceutical MES, critical functions requiring validation emphasis include: electronic batch record capture and approval workflow, e-signature controls for batch review, audit trail for all GxP record changes, process parameter limit enforcement, deviation detection and escalation, and data transfer to QMS/LIMS. Non-critical functions (UI preferences, report formatting) can use a reduced testing approach.
Inspection-ready validation package
An inspection-ready CSV package contains: Validation Plan, URS with GxP risk classification, Supplier Assessment, Configuration Specification, IQ/OQ/PQ protocols and execution records, Validation Summary Report, and ongoing change control log. Under CSA, critical thinking rationale documents replace some scripted test scripts — explaining why a function was not scripted, based on risk and supplier evidence.
How to use this page
Use this Computer System Validation (CSV) and CSA for Pharma page as a planning checkpoint before vendor selection, architecture review, validation scoping or implementation sequencing. The strongest next step is to compare the guidance with your current SOPs, system inventory, batch records, data flows and QA review routines so the discussion starts from evidence instead of assumptions.
Evidence to prepare
For Computer System Validation (CSV) and CSA for Pharma, prepare the records, owners, risks and decision criteria linked to traditional csv vs modern csa approach, critical functions in pharma mes validation, inspection-ready validation package. Useful evidence includes current process maps, interface lists, audit trail expectations, exception workflows, data retention rules and the business reason for changing the current operating model.
Frequently asked questions
What is the difference between IQ, OQ, and PQ in pharmaceutical CSV?
IQ (Installation Qualification) verifies that the system is installed correctly in its intended environment: hardware meets specification, software is the correct version, system is connected to required interfaces and documentation is available. OQ (Operational Qualification) verifies that the system operates as specified under defined operating conditions: configured functions work correctly, access controls enforce authorisation, audit trails capture required events. PQ (Performance Qualification) verifies that the system consistently performs its intended purpose under production conditions — using representative data, production users and normal operational volumes.
Can supplier testing documentation replace IQ/OQ testing under FDA CSA?
FDA's CSA guidance allows supplier test documentation to substitute for in-house scripted testing for non-critical, low-risk functions, provided the supplier testing is reviewed and found adequate. For critical functions — those affecting GxP records, audit trails and e-signatures — site-specific testing remains required to confirm that the configuration in the production environment behaves as expected. Supplier test documentation reduces testing burden but does not eliminate site validation responsibility for critical functions.
How often should a validated computer system undergo periodic review?
GAMP 5 and EU GMP Annex 11 both require periodic review of validated systems — typically annually for high-risk systems and every 2–3 years for lower-risk configurations. Periodic review covers: change control history, security access review, backup and restore test, audit trail review, and an assessment of whether the system continues to meet its validated specification. A periodic review does not require full revalidation unless significant changes are identified.